TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Form 10-Q — Nov 2, 2026
Tactile Medical reported Q3 2026 revenue of $91.9 million, up 7% year-over-year, with lymphedema product revenue up 13% offset by a 25% decline in airway clearance sales tied to the AffloVest Gen 6 DME inventory transition. Nine-month revenue rose 12% to $252.8 million and net income jumped 56% to $13.2 million, though Q3 net income fell 13% to $7.2 million (diluted EPS $0.31 vs $0.36) as operating expenses grew 13% on higher personnel and IT costs.
Key figures
- Eps
- 0.31
- Revenue
- 91858000
- Net Income
- 7160000
- Revenue Yoy
- 7% (Q3); 12% (nine months)
- Total Assets
- 291294000
- Cash Position
- 75110000
- Shares Outstanding
- 22495939
- Gross margin q3
- 77%
- Nine month revenue
- 252823000
- Nine month net income
- 13182000
- Revolver capacity usd
- 40000000
- Nine month eps diluted
- 0.57
- Buybacks nine months usd
- 12528000
- Q3 net income prior year
- 8209000
- Q3 eps prior year diluted
- 0.36
- Lymphedema revenue q3 growth
- 13%
- Shares repurchased nine months
- 502762
- Operating cash flow nine months
- 14893000
- Airway clearance revenue q3 change
- -25%
- Contingent consideration liability
- 4924000
- Remaining buyback authorization usd
- 12500000
- Lymphatech total purchase consideration
- 12093000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.